Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
2019 · The Lancet · 1,172 citations
https://doi.org/10.1016/s0140-6736(19)33041-7
A
Andreas E. Kremer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
390
Papers
9.7K
Citations
51
h-index
118
i10-index
Andreas E. Kremer is an academic researcher from University of Zurich. The author has contributed to research in topics: Liver Diseases and Immunity & Liver Disease Diagnosis and Treatment & Dermatology and Skin Diseases. The author has an h-index of 51, co-authored 332 publications.
ORCID: 0000-0002-9263-948XPapers by this author
worksVascular occlusion by neutrophil extracellular traps in COVID-19
2020 · EBioMedicine · 472 citations
https://doi.org/10.1016/j.ebiom.2020.102925
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
2021 · Annals of the Rheumatic Diseases · 195 citations
https://doi.org/10.1136/annrheumdis-2021-220461
Mas-related G protein–coupled receptor X2 and its activators in dermatologic allergies
2020 · Journal of Allergy and Clinical Immunology · 123 citations
https://doi.org/10.1016/j.jaci.2020.08.027
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
2023 · Hepatology · 105 citations
https://doi.org/10.1097/hep.0000000000000395
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
2019 · Clinical Gastroenterology and Hepatology · 97 citations
https://doi.org/10.1016/j.cgh.2019.05.013
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat